Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29263587 | 0.86 | AGTR1 (0.37) | CNR2AGTR1AGTR2CNR1 | |
| SCHEMBL31025957 | 0.85 | TLR7 (0.34) | CNR2CNR1TLR7NR1H2 | |
| SCHEMBL25301644 | 0.85 | TLR7 (0.34) | CNR2CNR1TLR7NR1H2 | |
| SCHEMBL25302358 | 0.81 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL31270623 | 0.81 | GLS (0.39) | — | |
| SCHEMBL25819006 | 0.81 | GLS (0.39) | — | |
| SCHEMBL25256470 | 0.81 | TLR7 (0.34) | TLR7 | |
| SCHEMBL25256105 | 0.80 | TLR7 (0.40) | TLR7 | |
| SCHEMBL30586085 | 0.79 | TLR7 (0.34) | TLR7 | |
| SCHEMBL25301747 | 0.79 | TLR7 (0.34) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4516321-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4458830-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118829451-A | Antibody drug conjugate, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2023207710-A9 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118201933-A | Tri-fused ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023207710-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023125121-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | CD47, ABCB1, EGFR | CNR2 3312/4885AGTR1 4529/4885AGTR2 4490/4885 |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | CNR2 519/4885AGTR1 740/4885AGTR2 859/4885 |
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B1, CYP11B2, CYP2D6 | CNR2 245/4885AGTR1 155/4885AGTR2 259/4885 |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | CNR2 519/4885AGTR1 740/4885AGTR2 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.